Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study
-
- Aoki Kazutaka
- Internal Medicine, Kanagawa Dental University, Yokosuka, Japan Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan
-
- Kamiyama Hiroshi
- Kamiooka Diabetes Metabolism Naika Clinic, Yokohama, Japan
-
- Takihata Masahiro
- Miura Central Clinic, Miura, Japan
-
- Taguri Masataka
- Department of Data Science, Yokohama City University School of Data Science, Yokohama, Japan
-
- Shibata Eriko
- Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan
-
- Shinoda Kazuaki
- Konandai Naika Clinic, Yokohama, Japan
-
- Yoshii Taishi
- Oppama Yoshii Naika Clinic, Yokosuka, Japan
-
- Nakajima Shigeru
- Nakajima Naika Clinic, Yokosuka, Japan
-
- Terauchi Yasuo
- Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Search this article
Abstract
<p>The mechanism for the cholesterol-lowering effect of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) remains unknown in patients with type 2 diabetes. We evaluated the effect of liraglutide on serum lipid profiles, including cholesterol synthesis and absorption markers, during daily clinical practice in Japanese patients with type 2 diabetes. We enrolled 38 patients with type 2 diabetes mellitus who were not treated with a GLP-1 RA (≥20 years of age, HbA1c ≥6.5%). Liraglutide, a GLP-1 RA, was administered subcutaneously once a day for three months to these patients. Blood samples and body weights were collected at 0, 1, and 3 months. Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at 1 month, and non-high-density lipoprotein cholesterol (non-HDL-C) and calculated TC at 1 and 3 months, were decreased, while the cholesterol synthesis and cholesterol absorption markers were unchanged by this treatment. In patients with LDL-C levels over 100 mg/dL, LDL-C, non-HDL-C, TC, and calculated TC levels were decreased significantly by the treatment at 1 and 3 months, and the cholesterol absorption marker, campesterol, was decreased at 3 months. The administration of liraglutide for 3 months decreased non-HDL-C and calculated TC significantly, while the cholesterol synthesis and absorption markers were not changed by this treatment.</p>
Journal
-
- Endocrine Journal
-
Endocrine Journal 67 (9), 957-962, 2020
The Japan Endocrine Society
